Patents Assigned to Hyal Pharmaceutical Corporation
-
Patent number: 5929048Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.Type: GrantFiled: June 5, 1995Date of Patent: July 27, 1999Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel S. Asculai
-
Patent number: 5914314Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.Type: GrantFiled: June 5, 1995Date of Patent: June 22, 1999Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel S. Asculai
-
Patent number: 5914322Abstract: A topically applied transdermally penetrating systemic independent acting pharmaceutical combination and formulation for the treatment of a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective non-toxic amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogueType: GrantFiled: June 6, 1995Date of Patent: June 22, 1999Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai
-
Patent number: 5910489Abstract: A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeautically effective non-toxic (to the patient) dosage amount of a drug for the treatment of the disease and/or condition of the skin and/or exposed tissue at the site of the pathology and/or trauma and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid to transport (to facilitate or cause the transport of) the drug to the site of the pathology and/or trauma of the disease or condition.Type: GrantFiled: August 19, 1994Date of Patent: June 8, 1999Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai
-
Patent number: 5852002Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.Type: GrantFiled: June 5, 1995Date of Patent: December 22, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel S. Asculai
-
Patent number: 5847002Abstract: The use of:(a) a non-steroidal anti-inflammatory agent,and(b) hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid,in the manufacture of a pharmaceutical composition for inhibiting, controlling and/or regressing angiogenesis in a therapy wherein dosage amounts taken from the composition each comprise:(1) a therapeutically effective amount of component (a); and(2) a therapeutically effective amount of the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, the pharmaceutical composition being characterized in that for each dosage amount taken from the pharmaceutical composition, the amount of components (a) and (b) inhibit, control and/or regress angiogenesis.Type: GrantFiled: June 5, 1995Date of Patent: December 8, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Derek A. Willoughby, Chandan Alam, Samuel Simon Asculai, Rudolf Edgar Falk, David William Harper
-
Patent number: 5834444Abstract: A method is provided of preventing arterial restenosis of an animal after the arteries have been traumatized. The method comprises the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof to the animal to prevent narrowing of the arteries. The form of hyaluronic acid is selected from hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than 750,000 daltons.Type: GrantFiled: September 23, 1993Date of Patent: November 10, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Eva Anne Turley, Samuel Simon Asculai
-
Patent number: 5830882Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.Type: GrantFiled: June 5, 1995Date of Patent: November 3, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel S. Asculai
-
Patent number: 5827834Abstract: A method of treating anorectal disease is provided which comprises applying to anorectal tissue in need of such treatment an effective amount of a composition comprising a pharmaceutically acceptable carrier and hyaluronic acid or a pharmaceutically acceptable salt thereof in an amount8 of up to about 10% by weight.Type: GrantFiled: August 5, 1994Date of Patent: October 27, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel S. Asculai
-
Patent number: 5824658Abstract: A method of treating pain topically, said method comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage amount comprising (1) a non-steroidal anti-inflammatory drug (NSAID) in a therapeutically effective amount to treat pain of the skin or exposed tissue and (2) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, its non-toxic salts and combination thereof being between 1% and 3% by weight of the composition, characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin or exposed tissue and in a dosage amount in which component (2) exceeds 10 mg/cm.sup.Type: GrantFiled: August 7, 1995Date of Patent: October 20, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai
-
Patent number: 5817642Abstract: A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof, homologues, analogues, derivatives, esters, complexes, fragments and subunits.Type: GrantFiled: August 15, 1995Date of Patent: October 6, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai
-
Patent number: 5817644Abstract: A method of treating a disease or condition in a human treatable by a medicine and/or therapeutic agent which may be transported by an agent to the site in need of treatment in the body and which agent may also transport the medicine and/or therapeutic agent to the liver (by for example, the transport agent binding to receptors on the liver) is provided comprising:(a) administering an effective non-toxic amount of a first agent which does not bind to receptors at the site in need of treatment but which binds with receptors of the liver thereby "down regulating" the liver; and,(b) thereafter administering an effective non-toxic amount of a medicine and/or therapeutic agent and an effective amount of a second agent which is a transport agent and is a different agent from the first agent which binds to the site in need of treatment and would be capable of binding to the sites of the liver if the liver had not been "down regulated" so that its binding capacity for the second agent has been substantially reduced bType: GrantFiled: December 7, 1995Date of Patent: October 6, 1998Assignee: Hyal Pharmaceutical CorporationInventor: Stefan Gustafson
-
Patent number: 5811410Abstract: A method of administering a medicinal agent and an effective amount of a form of hyaluronic acid for decreasing side effects associated with using the agent alone in treating a disease or condition in mammals is disclosed. The agent may be a non-steroidal anti-inflammatory drug (NSAID). The amount of hyaluronic acid is sufficient enough to provide a dosage greater than 200 mg/70 kg person. The molecular weight of the form of hyaluronic acid may be less than 750,000 daltons.Type: GrantFiled: June 5, 1995Date of Patent: September 22, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel S. Asculai
-
Patent number: 5792753Abstract: A topically administrable pharmaceutical composition is disclosed which comprises a therapeutically effective amount of a drug which inhibits prostaglandin synthesis, and an amount of a form of hyaluronic acid sufficient to transport the composition through the skin into the epidermis or dermis where the composition remains until discharged via the lymphatic system, wherein(a) the drug is 1-5% by weight of the composition, and(b) the form of hyaluronic acid is 1-3% by weight of the composition, has a molecular weight greater than about 150,000 daltons and less than 750,000 daltons, and is selected from the group consisting of hyaluronic acid and salts thereof.Type: GrantFiled: February 17, 1993Date of Patent: August 11, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai
-
Patent number: 5767106Abstract: A method of treating a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into the area damaged by the disease or condition, the method comprising administering to the human an effective amount of hyaluronic acid and/or salts thereof for a period of time until the administration is no longer required.Type: GrantFiled: August 25, 1994Date of Patent: June 16, 1998Assignee: Hyal Pharmaceutical CorporationInventors: Eva Anne Turley, Samuel Simon Asculai
-
Patent number: 5674857Abstract: A pharmaceutical composition comprising an effective non-toxic amount of hyaluronic acid (HA) and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and units of HA in association with a suitable diluent or pharmaceutically acceptable carrier for use in treating ischemia damage in tissue.Type: GrantFiled: February 23, 1994Date of Patent: October 7, 1997Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai, Ehud Shmuel Klein
-
Patent number: 5639738Abstract: A method of treating a mammal for a condition of the skin or exposed tissue selected from the group consisting of basal cell carcinoma and actinic keratosis is provided. The method consists essentially of topically administering to the site of the condition, more than once per day over a period of days sufficient to treat the condition, a non-toxic effective dosage amount of a composition consisting essentially of(a) a non-steroidal anti-inflammatory drug (NSAID) in an amount sufficient to block prostaglandin synthesis,(b) hyaluronic acid or a pharmaceutically acceptable salt thereof in an amount effective to transport said NSAID into the skin or exposed tissue at the site of the condition. The concentration of the hyaluronic add or salt thereof is between 1-3% by weight of the composition. The molecular weight of the hyaluronic acid or salt thereof is between 150,000 and 750,000 Daltons. A pharmaceutical excipient suitable for topical application is included.Type: GrantFiled: February 21, 1992Date of Patent: June 17, 1997Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai
-
Patent number: 5614506Abstract: For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid to the animal to prevent narrowing of the tubular walls.Type: GrantFiled: August 3, 1994Date of Patent: March 25, 1997Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf E. Falk, Samuel S. Asculai, Eva A. Turley
-
Patent number: 5079236Abstract: A heat stable, purified, pyrogen-free, heat sterilized fraction of hyaluronic acid suitable for use in formulations for intra-articular treatment of animals which includes minor amounts of sulphated mucopolysaccharides, sulphated ash, chlorides, solvents and less than 0.6% protein, having a molecular weight of less than 750,000 and exhibiting a specific absorbance of a 1% solution at A257nm of less than 3. A formulation for intra-articular treatment of animals including an aqueous solution of the heat stable fraction of hyaluronic acid and preservatives, such as sodium benzoate, methylparaben and propylparaben, having a pH of 6.8-8.0 at 25.degree. C. A method of preparing a formulation for intra-articular treatment of animals involving adding and dissolving methyl parahydroxybenzoate, propyl parahydroxybenzoate and sodium benzoate in hot water, mixing the preservative solution to dissolve the parabens, adding sodium hyaluronate in the solution, adjusting the pH of the resultant solution to 6.8-8.Type: GrantFiled: May 27, 1987Date of Patent: January 7, 1992Assignee: Hyal Pharmaceutical CorporationInventors: Alan Drizen, Anita Aviad
-
Patent number: 5077296Abstract: A method of treating a horse suffering from navicular disease which involves administering an amount of a composition including pentoxifylline in a daily dose for a sufficient period of time effective to alleviate lameness in horses resulting from navicular disease. A pharmaceutical composition including an effective amount of pentoxifylline and a pharmaceutically acceptable carrier for alleviating lameness resulting from navicular disease.Type: GrantFiled: December 3, 1987Date of Patent: December 31, 1991Assignee: Hyal Pharmaceutical CorporationInventor: Alan Drizen